Nivolumab - Biologic Drug Details

Summary for nivolumab

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	2
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for nivolumab

Recent Clinical Trials for nivolumab

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
British Columbia Cancer Agency	PHASE3
Hospices Civils de Lyon	PHASE2
Guliz Ozgun	PHASE3

See all nivolumab clinical trials

Pharmacology for nivolumab

Mechanism of Action	Programmed Death Receptor-1-directed Antibody Interactions
Established Pharmacologic Class	Programmed Death Receptor-1 Blocking Antibody

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for nivolumab Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for nivolumab Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Bristol-myers Squibb Company	OPDIVO	nivolumab	Injection	125554		2036-04-28	DrugPatentWatch analysis and company disclosures
Bristol-myers Squibb Company	OPDIVO	nivolumab	Injection	125554		2038-12-21	DrugPatentWatch analysis and company disclosures
Bristol-myers Squibb Company	OPDIVO	nivolumab	Injection	125554		2036-11-30	DrugPatentWatch analysis and company disclosures
Bristol-myers Squibb Company	OPDIVO	nivolumab	Injection	125554		2036-07-14	DrugPatentWatch analysis and company disclosures
Bristol-myers Squibb Company	OPDIVO	nivolumab	Injection	125554		2037-06-02	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for nivolumab Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Bristol-myers Squibb Company	OPDIVO	nivolumab	Injection	125554		2036-06-24	Patent claims search
Bristol-myers Squibb Company	OPDIVO	nivolumab	Injection	125554		2035-02-04	Patent claims search
Bristol-myers Squibb Company	OPDIVO	nivolumab	Injection	125554		2036-07-12	Patent claims search
Bristol-myers Squibb Company	OPDIVO	nivolumab	Injection	125554		2035-08-27	Patent claims search
Bristol-myers Squibb Company	OPDIVO	nivolumab	Injection	125554		2033-08-30	Patent claims search

International Patents for nivolumab

Country	Patent Number	Estimated Expiration
Japan	2018039835
Hungary	S1500066
Japan	2022071038
Japan	2023002567
Russian Federation	2406760

Supplementary Protection Certificates for nivolumab

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2016C/001	Belgium		PRODUCT NAME: KEYTRUDA (PEMBROLIZUMAB; AUTHORISATION NUMBER AND DATE: EU/1/15/1024 20150721
SPC/GB16/001	United Kingdom		PRODUCT NAME: PEMBROLIZUMAB; REGISTERED: UK EU/1/15/1024 20150721
C 2015 054	Romania		PRODUCT NAME: NIVOLUMAB; NATIONAL AUTHORISATION NUMBER: EU/1/15/1014; DATE OF NATIONAL AUTHORISATION: 20150619; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/15/1014; DATE OF FIRST AUTHORISATION IN EEA: 20150619
PA2015052,C2161336	Lithuania		PRODUCT NAME: NIVOLUMABAS; REGISTRATION NO/DATE: EU/1/15/1014 20150624
300783	Netherlands		PRODUCT NAME: NIVOLUMAB; REGISTRATION NO/DATE: EU/1/15/1014 20150619

Market Dynamics and Financial Trajectory of Nivolumab

Last updated: February 27, 2026

What is the current market landscape for nivolumab?

Nivolumab, marketed as Opdivo by Bristol-Myers Squibb (BMS), is a PD-1 immune checkpoint inhibitor approved across multiple cancer indications. As of 2022, it holds a leading position in the oncology immunotherapy market. The drug’s global sales in 2022 reached approximately $9 billion, representing a growth rate of around 10% year-over-year. This constitutes one of the highest revenues among immune checkpoint inhibitors.

Major indications include melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma, and head and neck squamous cell carcinoma. Additional approvals for gastric, bladder, and other solid tumors expand its market reach.

What are key drivers influencing nivolumab’s financial trajectory?

1. Expanding Indications

Nivolumab received FDA approval for 15+ cancer types, including second-line indications and combination therapies. The expansion into earlier stages of disease increases patient populations and revenue potential.

2. Market Penetration and Competition

Nivolumab faces competition from pembrolizumab (Keytruda) by Merck and atezolizumab (Tecentriq) by Roche. While pembrolizumab maintains a slight edge in some indications, nivolumab remains the dominant choice in others due to differing dosing regimens and approved combinations.

3. Geographic Market Growth

Emerging markets like China (via JV with BeiGene) are crucial. The China National Medical Products Administration (NMPA) approved nivolumab for multiple indications in 2020. Local manufacturing lowers costs and increases access, enabling faster market penetration.

4. Strategic Collaborations and Combinations

Partnerships with biotech firms and academic institutions have led to novel combination regimens. The therapy's performance in combination with chemotherapy or other immunotherapies significantly influences future sales.

5. Patent and Regulatory Status

Patent protection in key markets extends through 2028-2030, with biosimilar competition expected post-expiry. Regulatory advances, such as accelerated approvals and supplemental indications, also impact revenue potential.

How has nivolumab's revenue trended historically?

Year	Global Sales (USD billions)	Growth Rate	Key Factors
2017	3.6	N/A	First US approval, initial launches
2018	4.4	22%	Expanded indications, increased adoption
2019	8.3	89%	US approval for non-small cell lung cancer; early signs of global expansion
2020	8.5	2.4%	COVID-19 impact, sustained demand
2021	8.9	4.7%	Broader approvals and dose optimization
2022	~9.0	1.1%	Market maturation, new biosimilar entrants

What are the future revenue projections?

Analysts project nivolumab’s global revenue to reach approximately $11.5 billion by 2025. Growth will depend on:

• Indication Expansion: Approval for additional cancers, including ovarian and mesothelioma, expected over the next 2 years.
• Combination Therapies: Trials demonstrating superiority or non-inferiority in combination may boost adoption.
• Market Penetration: Deeper penetration into China, India, and Latin America, driven by local manufacturing.
• Patent Landscape: Patent cliff around 2028 necessitates shifts towards biosimilars, potentially halving price points.

What are risks and challenges?

• Biosimilar Competition: Entry of biosimilars post-2028 could erode revenue, depending on market acceptance.
• Regulatory Delays: Slow approval processes or setbacks in new indications diminish growth prospects.
• Market Saturation: Mature markets nearing penetration limits could temper sales growth.
• Pricing Pressures: Payer negotiations and policy reforms targeting high-cost biologics could restrict revenue.

Summary of key financial metrics

Metric	2022 Estimate	Notes
Total revenue	~$9 billion	Dominant among PD-1 inhibitors
Market share (immunotherapy)	~45%	Slightly below pembrolizumab, which holds ~50%
R&D expenditure	$1.5 billion	Approximately 17% of sales invested in pipeline R&D

Key Takeaways

• Nivolumab remains a top-tier immunotherapy in oncology, with steady revenue growth driven by indication expansion and geographic penetration.
• Competition, biosimilar entry, and regulatory factors pose threats to sustained revenue.
• Strategic collaborations and combination regimens are pivotal to maintaining market share.
• Expiration of patents around 2028-2030 could impact pricing power and revenue streams.

FAQs

Q1: How is nivolumab performing compared to pembrolizumab?
Nivolumab generates slightly less revenue but remains competitive, especially in certain indications like renal cell carcinoma. The market is highly contested, with both therapies often approved concurrently.

Q2: What new indications are expected to drive future growth?
Approved expanded indications include first-line lung cancer, stomach and esophageal cancers, and certain hematologic malignancies. Trials are ongoing for others, such as ovarian and mesothelioma.

Q3: How significant is patent expiration risk for nivolumab?
Patent expiry in major markets is expected around 2028-2030, opening the door for biosimilar competition, which could reduce prices and revenue.

Q4: Which regions will contribute most to future sales?
North America maintains the largest share, but China’s market growth due to local manufacturing and approvals is rapidly increasing its contribution.

Q5: What role do combination therapies play in nivolumab’s financial outlook?
Combination therapies with chemotherapy, targeted agents, or other immunotherapies have shown improved outcomes in trials, correlating with potential revenue growth through broader use.

---

References

[1] Bristol-Myers Squibb. (2022). Opdivo (Nivolumab) prescribing information.
[2] EvaluatePharma. (2022). World Preview 2023: Outlook to 2028.
[3] FDA. (2020). Nivolumab approvals and indications.
[4] IQVIA. (2022). Global Oncology Market Report.
[5] China NMPA. (2020). Approval of nivolumab for multiple indications.